Psilocybin vs. Cognitive Behavioral Therapy
Psychedelic therapy is a form of psychotherapy that involves the use of psychedelic drugs to treat mental health conditions. One such drug is psilocybin, which has been studied for its potential benefits in treating depression, anxiety, addiction, and other psychological disorders. In contrast to psilocybin therapy, cognitive behavioral therapy (CBT) is a type of talk therapy used to treat mental health issues for decades. This article explores the science behind and potential benefits of psilocybin and CBT for mental health conditions.
Psilocybin Therapy: Science and Potential Benefits
Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. When administered in a controlled therapeutic setting with the guidance of a trained therapist, it can produce powerful changes in perception, thought patterns, and emotions. During psilocybin-assisted therapy sessions, patients are encouraged to explore their inner experiences while under the influence of the drug. Depending on the dosage and individual physiology, the effects typically last between six to eight hours.
The mechanisms by which psilocybin produces its effects are not yet fully understood, but there are several theories as to how it works. One theory suggests that it decreases activity in certain areas of the brain associated with mood regulation, including the amygdala and hippocampus [1]. It may also affect serotonin receptors in the brain leading to changes in emotional processing [2]. Research suggests that these changes can lead to long-term mood and emotional regulation improvements.
In terms of potential benefits for mental health conditions, studies have shown that psilocybin may be effective for depression, anxiety, addiction, post-traumatic stress disorder (PTSD), and end-of-life distress. End-of-life distress is when people face a terminal illness and may be experiencing a lot of emotional pain.
Cognitive Behavioral Therapy: Science and Potential Benefits
Cognitive behavioral therapy (CBT) is an evidence-based type of talk therapy. It focuses on helping individuals recognize patterns between their thoughts, feelings, and behaviors so they can create new ways of thinking and behaving that will lead to a better life. It was developed by psychiatrist Aaron Beck in the 1960s but has since been adapted into many forms based on different theoretical frameworks, such as Acceptance Commitment Therapy or Dialectical Behavior Therapy [3].
At its core, CBT involves helping individuals identify maladaptive thoughts or beliefs they may have about themselves or situations they face which lead them to feel distressed or behave unhelpfully. The therapist then helps them challenge those thoughts using evidence from their own experience or from scientific research. Challenging these thoughts can help patients develop more helpful beliefs about themselves or their environment. They also work together on developing skills such as problem-solving techniques or relaxation strategies to help them manage difficult emotions more effectively when facing challenging situations.
Research suggests that CBT can effectively treat depression, anxiety disorders such as panic disorder or social phobia, post-traumatic stress disorder, addiction, and obsessive-compulsive disorder. Furthermore, it has been found effective at reducing symptoms related to chronic pain and improving quality-of-life measures such as self-esteem.
Current State Of Research
Preliminary studies suggest that both psilocybin therapy and CBT may have potential benefits when used in combination with standard treatments like medication or talk therapy. For instance, one study found that combining psilocybin with psychotherapy was associated with significant decreases in depressive symptoms compared to those who only received psychotherapy alone[4]. Similarly, another study found that adding CBT to antidepressant treatment was associated with greater improvements in symptoms than either treatment alone [5].
Legal Status And Availability
The legal status of psilocybin therapy is not uniform, varying across countries and regions due to diverse laws on psychoactive substances. For example, in Switzerland and Portugal, the medical use of psilocybin is permitted. In these nations, psychiatrists can recommend psilocybin-assisted therapy to patients diagnosed with specific mental health disorders, and psilocybin is dispensed under strictly regulated conditions. A few other countries, such as the Netherlands and Israel, also allow the medical use of psilocybin. Similar to Switzerland and Portugal, psychiatrists in these countries can suggest psilocybin-assisted therapy to patients with certain mental illnesses, and the administration of psilocybin is overseen with strict control.
While many healthcare providers around the world widely accept CBT as an effective treatment option for certain mental health conditions, access can vary due to differences in insurance coverage for such services.
Risks And Precautions
Both psilocybin therapy and CBT can have risks and precautions that should be considered before starting treatment. Psilocybin therapy should only be done with the supervision of a trained healthcare professional. If the dose is incorrect, it can cause problems like anxiety or panic attacks during the session. It is also important to understand that psilocybin therapy does not always work and is not a replacement for other medical treatments like medication. If you decide to try psilocybin therapy, you should avoid taking other drugs and talk to your therapist about any medical conditions you have.
CBT also has risks. You may feel uncomfortable discussing personal topics during sessions or distressed during exposure exercises, which involve facing feared situations. CBT can also cause confusion or distress by challenging your existing beliefs about yourself and changing your identity structure. Results from CBT can vary depending on your motivation level and other personal factors.
Deciding which treatment approach is right for you can be a difficult and overwhelming process, and it's wise to carefully consider all of your options before making a decision. Both psilocybin therapy and cognitive-behavioral therapy have the potential to be effective in treating certain mental health conditions and may be even more successful in conjunction with traditional treatments.
At Psychly, we are committed to upholding the highest standards in our content creation process. We strive to ensure that all statements presented in our articles are supported by reliable, high-quality sources, such as peer-reviewed studies and reputable academic journals.
- The Psychly Team
- Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015). Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological psychiatry, 78(8), 572–581. https://doi.org/10.1016/j.biopsych.2014.04.010
- Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific reports, 10(1), 2214. https://doi.org/10.1038/s41598-020-59282-y
- Aaron T. Beck | Beck Institute. (2022, May 18). Beck Institute. https://beckinstitute.org/about/dr-aaron-t-beck/
- Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Mendel Kaelen, Bloomfield, M. A. P., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 3(7), 619–627. https://doi.org/10.1016/s2215-0366(16)30065-7
- Dunlop, B., Loparo, D., Kinkead, B., Mletzko-Crowe, T., Cole, S., Nemeroff, C., Mayberg, H., & Craighead, W. (n.d.). Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. https://doi.org/10.1176/appi.ajp.2018.18091075)